Based on the Bright Minds Biosciences Inc stock forecast from 0 analysts, the average analyst target price for Bright Minds Biosciences Inc is not available over the next 12 months. Bright Minds Biosciences Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bright Minds Biosciences Inc is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, Bright Minds Biosciences Inc’s stock price was CAD 54.54. Bright Minds Biosciences Inc’s stock price has changed by -6.56% over the past week, +16.07% over the past month and +2,627.00% over the last year.
No recent analyst target price found for Bright Minds Biosciences Inc
No recent average analyst rating found for Bright Minds Biosciences Inc
Company Overview Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York. Read Less
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of...Read More
Frequently Asked Questions About Bright Minds Biosciences Inc (DRUG:CA) Stock
Stock Target Advisor's fundamental analysis for Bright Minds Biosciences Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on DRUG:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on DRUG:CA's stock to indicate what its average analyst target is.
DRUG:CA stock's Price/Earning ratio is 0.30.
Our analysis grades DRUG:CA stock's Price / Earning ratio at A+. This means that DRUG:CA stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the CNSX exchange.
Based on this DRUG:CA may be undervalued for its sector.
The last closing price of DRUG:CA's stock was CAD 54.54.
The most recent market capitalization for DRUG:CA is CAD 0.38B.
Unfortunately we do not have enough analyst data on DRUG:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bright Minds Biosciences Inc's stock.
As per our most recent records Bright Minds Biosciences Inc has 0 Employees.
Bright Minds Biosciences Inc's registered address is 19 Vestry Street, New York, NY, United States, 10013.
You can get more information about it from Bright Minds Biosciences Inc's website at https://brightmindsbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Bright Minds Biosciences Inc (DRUG:CA) Stock
Stock Target Advisor's fundamental analysis for Bright Minds Biosciences Inc's stock is Slightly Bullish .
Unfortunately we do not have enough data on DRUG:CA's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on DRUG:CA's stock to indicate what its average analyst target is.
DRUG:CA stock's Price/Earning ratio is 0.30.
Our analysis grades DRUG:CA stock's Price / Earning ratio at A+. This means that DRUG:CA stock's Price/Earning ratio is above 0% of the stocks in the Biotechnology sector in the CNSX exchange.
Based on this DRUG:CA may be undervalued for its sector.
The last closing price of DRUG:CA's stock was CAD 54.54.
The most recent market capitalization for DRUG:CA is CAD 0.38B.
Unfortunately we do not have enough analyst data on DRUG:CA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bright Minds Biosciences Inc's stock.
As per our most recent records Bright Minds Biosciences Inc has 0 Employees.
Bright Minds Biosciences Inc's registered address is 19 Vestry Street, New York, NY, United States, 10013.
You can get more information about it from Bright Minds Biosciences Inc's website at https://brightmindsbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DRUG:CA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
